Primecap Management Company Stake in Lilly Eli & Co (LLY) Decreased by $33.27 Million; Shares Rose

Eli Lilly and Company (NYSE:LLY) Corporate LogoDuring Q3 2018 the big money sentiment increased to 0.98. That’s change of 0.14, from 2018Q2’s 0.84. 37 investors sold all, 399 reduced holdings as LLY ratio improved. 286 grew holdings while 141 funds bought holdings. Funds hold 794.28 million shares thus 1.80% less from 2018Q2’s 808.82 million shares. Berkshire Asset Mngmt Lc Pa holds 0.1% of its capital in Eli Lilly and Company (NYSE:LLY) for 11,505 shs. Fifth Third Comml Bank, a Ohio-based fund reported 121,902 shs. Veritable LP owns 30,953 shs for 0.07% of their capital. Monarch owns 4,723 shs. Cohen Klingenstein Ltd Limited Liability Company invested 1.29% of its capital in Eli Lilly and Company (NYSE:LLY). 1832 Asset Limited Partnership reported 0.06% of its capital in Eli Lilly and Company (NYSE:LLY). Cipher Capital Limited Partnership owns 55,738 shs for 1.12% of their capital. Wellington Group Incorporated Limited Liability Partnership holds 1.21% of its capital in Eli Lilly and Company (NYSE:LLY) for 53.60M shs. Security Natl Trust has invested 0.46% in Eli Lilly and Company (NYSE:LLY). Caxton Associate Ltd Partnership reported 2,333 shs. Highstreet Asset Management Inc invested 0.09% of its capital in Eli Lilly and Company (NYSE:LLY). Checchi Advisers Ltd Liability accumulated 12,280 shs. Winslow Evans And Crocker invested 0.27% in Eli Lilly and Company (NYSE:LLY). Kistler reported 732 shs. Ifrah Svcs holds 8,011 shs.

LLY registered $285.41 million net activity with 0 buys and 26 sales since August 15, 2018. Zulueta Alfonso G also sold $802,480 worth of Eli Lilly and Company (NYSE:LLY) shs. $2.82 million worth of Eli Lilly and Company (NYSE:LLY) was sold by O’Neill Myles. $63,342 worth of Eli Lilly and Company (NYSE:LLY) was sold by Zakrowski Donald A.

The stake In Lilly Eli & Co (LLY) was decreased held by Primecap Management Company. According to 2018Q3 Securities and Exchange filling the decrease is 0.56%. The company’s stock popped up 7.21% while Primecap Management Company sold 310,946 shares. At the end of 2018Q3, the 54.79 million shares of the major pharmaceuticals company held by the institutional investor were priced at $5.88 billion, down from 55.10M at the end of the previous reported quarter. $120.69B is the market cap of Lilly Eli & Co. LLY reached $119.65 during the last trading session after $0.16 change.Eli Lilly and Company has 12.74M shares volume, 137.35% up from normal. LLY is uptrending and has moved 32.86% since February 14, 2018. LLY outperformed by 32.86% the S&P500.

Primecap Management Company rose its stake in Flex Ltd (NASDAQ:FLEX) by 7.67M shares to 65.01M shares, valued at $852.95M in 2018Q3, according to the filing. It operates about $87.86B and $148.14 billion US Long portfolio. Primecap Management Company has risen its stake in Glaukos and also increased its holding in Irobot Corp (NASDAQ:IRBT) by 300,600 shares in the quarter, for a total of 4.16 million shares.

For more Eli Lilly and Company (NYSE:LLY) news brought out briefly go to:,,, or The titles are as follows: “Lilly (LLY) to Initiate Divestiture of its Remaining Interest in Elanco Animal Health (ELAN) –” brought out on February 08, 2019, “Lilly’s dual GIP and GLP-1 receptor agonist shows positive action in mid-stage T2D study; shares up 3% premarket – Seeking Alpha” on October 04, 2018, “Trade of the Day: Eli Lilly (LLY) –” with a publish date: September 27, 2018, “Key Takeaways from Eli Lilly’s (LLY) Q4 Earnings Report –” and the last “Lilly announces financial guidance – Seeking Alpha” with publication date: December 19, 2018.

Eli Lilly and Company (NYSE:LLY) Ratings Coverage

Total analysts of 7 have positions in Eli Lilly (NYSE:LLY) as follows: 3 rated it a “Buy”, 0 with “Sell” and 4 with “Hold”. The positive are 43%. Since September 7, 2018 according to StockzIntelligence Inc Eli Lilly has 9 analyst reports. On Monday, November 26 the rating was downgraded by Citigroup to “Neutral”. The stock rating was maintained by Barclays Capital with “Overweight” on Friday, October 12. On Wednesday, October 3 the rating was maintained by BMO Capital Markets with “Market Perform”. In Tuesday, September 18 report Barclays Capital maintained it with “Overweight” rating and $112 target. In Friday, September 7 report Barclays Capital maintained it with “Overweight” rating and $107 target. The company rating was maintained by JP Morgan on Wednesday, September 26. On Wednesday, October 31 Credit Suisse upgraded the shares of LLY in report to “Neutral” rating.

Eli Lilly and Company (NYSE:LLY) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.